Drug major Cipla has received an order from a US district court that the sale of its animal healthcare product, ‘PetArmor Plus’, has infringed on the patent held by Merial Ltd.
“The company has received an order dated June 21, 2011, from a US District Court, Middle District of Georgia, against a petition filed by Merial Ltd ruling that the sales of PetArmor Plus allegedly infringed a patent held by Merial Ltd,” Cipla said in a filing to the Bombay Stock Exchange today.
Future sales of PetArmor Plus have been suspended in the United States, it added.
The district court has stayed the above order for 60 days to enable the company to appeal, Cipla said, adding that it is in the process of filing an appeal against the order.
“There is no determination as yet by the court on the financial implication of the patent infringement,” itsaid.
Meanwhile, the company shares closed at Rs 330.35 on the BSE today, down 0.47 per cent from the previous close.